The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Dendritic Cells In Innate Immunity And Their Potential Clinical Manipulation
Funder
National Health and Medical Research Council
Funding Amount
$443,946.00
Summary
Dendritic cells (DC) are rare cells that are crucial in response to infection and surveillance of damaged tissues. We aim to understand the tools that are expressed by DC that allow them to sense pathogens and the functions of different DC types once a pathogen has been detected. The ultimate aim is to be able to understand and harness the functions of different DC so that we may directly target them upon demand to aid in the course of infection or potentially as tumour therapy.
During injury or infection, our body’s immune system protects us by launching inflammation. But uncontrolled inflammation drives common diseases such as cancer, diabetes, Alzheimer’s and Parkinson's. This research program will reveal how the body deactivates inflammasomes – protein complexes at the heart of inflammation and disease – so we can design better drugs for treating patients with inflammation-driven disease.
During injury or infection, our body’s immune system protects us by launching inflammation. But uncontrolled inflammation drives common diseases such as cancer, diabetes and Alzheimer’s. This project will reveal how the body deactivates inflammasomes - protein complexes at the heart of inflammation and disease – so we can design better strategies for treating patients with inflammation-driven disease.
Structural And Functional Studies Of The Human IL-3 Receptor
Funder
National Health and Medical Research Council
Funding Amount
$307,946.00
Summary
This proposal will study a protein hormone that is implicated in blood cell cancers and inflammatory diseases and for which current treatments are inadequate. We will determine how the hormone receptor becomes activated, identify and characterise new agents that block this activation. This information will help in the development of new and highly specific drugs for use in certain cancers in inflammatory diseases.
Role For Dipeptidyl Peptidase-IV In The Innate Immune Response
Funder
National Health and Medical Research Council
Funding Amount
$302,123.00
Summary
The innate immune system is the bodyÍs first line of defence in fighting off infections by invading organisms. An inappropriate innate immune response can lead to the development of several inflammatory conditions such as inflammatory bowel disease. A malfunctioning innate immune response has been identified in children with IBD. This project will determine the role of a unique enzyme called DPIV in the development of innate immune responses and its potential as a therapeutic target for IBD.
The Identification And Characterisation Of A New DNA Receptor
Funder
National Health and Medical Research Council
Funding Amount
$656,498.00
Summary
The immune system has evolved to fight disease-causing microbes. First, it has to recognize that an infectious agent has invaded. To do this we have developed many probes (receptors) that sense microbial products. Detecting microbial DNA is a critical alarm bell. However, distinguishing pathogen DNA from our own DNA is difficult because both look alike. We have identified a new receptor that helps us identify bacterial DNA and alerts the immune system to the imminent danger.
Production Of Interferon Lambda By Dendritic Cell Subsets And Role In Adjuvant Effects Of Poly I:C
Funder
National Health and Medical Research Council
Funding Amount
$396,541.00
Summary
This proposal describes the identification of specific cells in mouse and humans that produce the anti-viral compound interferon-lambda. We propose to further characterise the mechanisms that induce interferon-lambda expression by these cell types and to decipher how this is controlled at the genetic level. We also aim to determine how the production of interferon lambda by these cell types can influence the immune response to viral infection.
Understanding Natural Killer Cell Development And Target Recognition
Funder
National Health and Medical Research Council
Funding Amount
$408,388.00
Summary
Immune detection and eradication or control of cancer and cancer immunotherapies are based in part on the idea that tumour-specific white blood cells can protect the body from tumour development, growth and metastases. While strong evidence supports this, the means by which these white cells first recognize the cancerous tissue is largely unknown. We will study a new family of white blood cell receptors that may be important in this recognition, either naturally or following therapy.
Investigating The Roles Of Non-coding RNAs In Inflammatory Signalling And Cancer
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
Inflammation occurs as part of the body's natural defenses against infection or injury, but can be damaging when unregulated and can lead to cancer. Although the protein factors critical for inflammation have been carefully studied it remains unknown how ribonucleic acid (RNA) molecules can modify and regulate inflammation. This project will identify RNA molecules that control inflammatory signalling, and further translate these findings to show they contribute to the progression of cancer.
Control Of Combined Simian-human Immunodeficiency Virus Infection Utilising NK Cells Mediating Antigen-specific Antibody Dependent Cellular Cytotoxicity - A Novel Vaccine Modality
Funder
National Health and Medical Research Council
Funding Amount
$432,587.00
Summary
Recently, progress was made in developing a vaccine against HIV. Our laboratory was selected to join a global collaboration trying to elucidate the key to this success. Attention has focused on non-neutralizing antibodies and our laboratory has developed a unique expertise in detecting such immune responses. This research will define, purify and manufacture these antibodies and test their ability to prevent HIV in animals with the ultimate aim of producing a vaccine for human use.